enGenes shows enhanced X-press protein yields at RPP conference
Press Release | enGenes Biotech GmbH
APRIL 10, 2019
Vienna, Austria: – Recombinant protein specialist manufacturer enGenes Biotech GmbH (enGenes) will show successful application of its proprietary enGenes-X-press technology in significantly improving recombinant protein yields on its return to the recombinant protein production conference RPP10 in Crete.
enGenes is a silver sponsor of the event and attended the previous meeting in Dubrovnik in 2017.
At this year’s meeting, enGenes will present a poster and an oral presentation.
Growth-decoupled recombinant protein production in E. coli
“The RPP meeting is the foremost forum in the field of recombinant protein production bringing together an international cast of leasing players from industry and academia,” commented enGenes Biotech CEO, Dr. Juergen Mairhofer, who will attend the meeting, along with enGenes’s employee Patrick Stargardt, currently working on his PhD thesis.
Patrick Stargardt will deliver an oral presentation on ‘Growth-decoupled recombinant protein production in Escherichia coli’ during the morning session on Day Two of the meeting, focusing on Cell Engineering for Recombinant Protein Production.
“Together, our presentations will showcase our latest achievements in developing our enGenes-X-press technology to deliver enhanced yields in recombinant protein production by fine tuning expression levels for example” said Mr. Stargardt.
“Our presence and sponsorship of this valuable meeting emphasize that, above all, we are a science-driven company,” he added.
About enGenes Biotech
enGenes Biotech GmbH (enGenes) is a contract research, development and manufacturing company that provides leading edge technologies and production services focused on recombinant proteins in bacteria. The company’s mission is to provide cost-effective and scalable production of recombinant proteins at a fraction of current cost, allied to a vision of developing a world-class portfolio of cutting-edge protein production technologies, relevant to a broad spectrum of application fields.
enGenes has developed advanced technologies to drive more cost-effective recombinant protein production processes., including its proprietary enGenes-X-press™ E. coli platform that achieves outstanding yields of soluble and active recombinant protein. enGenes-X-press has been successful applied for the manufacturing of enzymes and biopharmaceutical products that failed to give economically feasible yields in a conventional expression host.
enGenes Biotech offers development and manufacturing services tailored around the needs of pharmaceutical and industrial biotech companies. The services include expression strain and vector development, fermentation process development and optimization, downstream process development, production of purified protein, technology transfer and scale-up support with technology out-licensing and co-development opportunities.
The RPP conference is a biennial event that offers a comprehensive overview of current challenges and innovative solutions in recombinant protein production, focusing on the comparative physiology of microbial and higher eukaryotic platforms for protein production.
The 2019 RPP conference (RPP10) is a four-day event opening April 24 at the Creta Maris Hotel at Hersonissos near Heraklion.
The conference will build on the successes of previous meetings, which have attracted steadily increasing numbers of researchers from both academia and the bioprocessing industry. The meeting will address major areas and emerging trends in industrially relevant recombinant protein production, including host physiology under bioprocess conditions, cell engineering, industrial-scale processes and new-format or difficult to express proteins
The event is jointly organized by the European Federation of Biotechnology (EFB) Microbial Physiology Section in partnership with the Federation of European Microbiological Societies (FEMS). Further information at: http://www.efbiotechnology.org/RPP.
Dr. Juergen Mairhofer, CEO, enGenes Biotech
Tel: +43 1 93 46 707-0